PRAX News and Press, Praxis Precision Medicines Inc. From 06/22/23

Strong demand for financing including full exercise of overallotment option with net proceeds of $63.3 million Cash runway extended into Q1 2025 Phase 2 Photoparoxsymal Response (PPR) study to evaluate PRAX-628 expected to read-out by YE 2023 Plan to begin ulixacaltamide...

2023-06-16 05:59:42 ET Praxis Precision Medicines ( NASDAQ: PRAX ) shares fell 6.15% premarket on Friday after the biopharma company priced its securities offering to raise around $59.1M in gross proceeds. The offering comprises 55.15M ordinary share...

BOSTON, June 15, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imba...

2023-06-15 16:25:12 ET Praxis Precision Medicines ( NASDAQ: PRAX ) said Thursday it plans to conduct a public offering of its common stock. All shares in the offering will be offered by the company. The underwriters are expected to have a 30-day option to purchase up to an...

BOSTON, June 15, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imba...

2023-06-09 13:01:49 ET Praxis Precision Medicines ( NASDAQ: PRAX ) added ~4% on Friday after announcing results from an end-of-Phase 2 meeting with the FDA regarding plans to advance its lead candidate ulixacaltamide for Phase 3 development in movement disorder, Essential Tremor...

Phase 3 program to include one parallel group study and one randomized withdrawal study mADL11 as primary endpoint Single 60 mg/day dose to be tested BOSTON, June 09, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmac...

BOSTON, June 02, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imba...

2023-05-11 14:05:09 ET Praxis Precision Medicines press release ( NASDAQ: PRAX ): Q1 GAAP EPS of -$0.71. Revenue of $0.68M. For further details see: Praxis Precision Medicines GAAP EPS of -$0.71, revenue of $0.68M

2023-05-11 09:29:59 ET More economic data, earnings reports, performance outlooks from management teams, and the Federal Reserve are driving sentiment in the stock market today. Whether you’re trading penny stocks or higher-priced company shares, there’s no getting around ...